Morgan Stanley Books Archegos Loss, but Profit Hits New High 

The bank lost $911 million when Archegos Capital Management imploded last month, tarnishing a record-setting quarter.

Indianapolis FedEx Shooting Leaves at Least Eight Dead 

The gunman arrived at the parking lot, got out of his car and started shooting. After killing people outside and inside the facility, he apparently killed himself.

Apple Music Reveals How Much It Pays When You Stream a Song 

The company pays the music industry a penny per stream on its service, a disclosure it made as part of an effort by music-streaming services to show they are artist-friendly.

Hertz Bankruptcy Bidding War Heats Up With New Counteroffer 

Knighthead Capital Management and Certares Management, which previously offered to buy Hertz out of bankruptcy but were eclipsed by a competing group, returned with a sweetened bid.

Simon & Schuster Won't Distribute Policeman's Book About Breonna Taylor Shooting 

The book's author, Jonathan Mattingly, was one of the three Louisville police officers who fired their weapons during last year's raid.

ESG Insights - Johnson & Johnson Under the Microscope 

This week, The Wall Street Journal's ESG research analysts looked at J&J's vaccine pause, Microsoft's acquisition of Nuance, the Veolia-Suez deal, Air Canada and more.

Toshiba Shareholders May Finally Get Their Due 

Storied Japanese company Toshiba has a long history of governance problems, but the prospect of a bidding war means things could finally be looking up.

J&J Privately Asked Rival Vaccine Makers to Probe Clot Risks 

AstraZeneca was interested in joining forces to investigate the safety issue and communicate vaccine benefits and risks, but Pfizer and Moderna didn't see the need for group action.

Mercedes-Benz Faces an Open Road Today, Traffic Tomorrow 

Two exceptionally profitable quarters for the luxury-car brand highlight what Daimler has to lose from the transition to electric vehicles.

Lilly Seeks to End U.S. Use of Single Covid-19 Antibody Drug Alone 

The drugmaker said it will distribute a drug cocktail containing bamlanivimab and a second antibody, etesevimab, that studies indicate together neutralize more of the emerging Covid-19 variants.


(END) Dow Jones Newswires

April 16, 2021 13:15 ET (17:15 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.